Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Basic activities like bathing or dressing become painful
Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist with no MHRA marketing authorisation in the UK as of 2025
"The most common areas will be the lower part of the face and the neck," explains the kalon Dermatology team
The practical takeaway is that even a temporary course of retatrutide provides metabolic value beyond the weight loss itself
It is not an approved drug, supplement, or generic alternative
When GLP-1 is secreted from L-cells through the TGR5 agonist, it stimulates GLP-1R in enterochromaffin cells and induces serotonin or 5-hydroxytryptamine (5-HT) secretion from these cells
US$ 21.91
US$ 24.79
US$ 26.07
US$ 28.09
